Royal Bank of Canada
DRUG

Royal Bank of Canada’s Bright Minds Biosciences DRUG Stock Holding History

Royal Bank of Canada’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30K Sell
406
-121
-23% -$9.74K ﹤0.01% 5715
2025
Q4 		$40K Buy
527
+372
+240% +$24.9K ﹤0.01% 5665
2025
Q3 		$9K Buy
155
+90
+138% +$3.49K ﹤0.01% 6517
2025
Q2 		$2K Sell
65
-524
-89% -$15.7K ﹤0.01% 6788
2025
Q1 		$21K Sell
589
-229
-28% -$8.38K ﹤0.01% 5898
2024
Q4 		$29K Buy
818
+158
+24% +$5.56K ﹤0.01% 5945
2024
Q3 		$1K Buy
660
+150
+29% +$169 ﹤0.01% 6699
2024
Q2 		$1K Sell
510
-102
-17% -$115 ﹤0.01% 6805
2024
Q1 		$1K Buy
612
+334
+120% +$585 ﹤0.01% 6778
2023
Q4 		$0 Buy
278
+182
+190% +$260 ﹤0.01% 7220
2023
Q3 		$0 Sell
96
-387
-80% -$1.03K ﹤0.01% 7180
2023
Q2 		$1K Buy
483
+67
+16% +$188 ﹤0.01% 6988
2023
Q1 		$1K Buy
416
+43
+12% +$143 ﹤0.01% 6874
2022
Q4 		$1K Buy
373
+54
+17% +$267 ﹤0.01% 7019
2022
Q3 		$2K Buy
319
+3
+0.9% +$19 ﹤0.01% 7004
2022
Q2 		$1K Buy
316
+268
+558% +$1.42K ﹤0.01% 7106
2022
Q1 		$0 Buy
+48
New +$538 ﹤0.01% 7794

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Royal Bank of Canada's DRUG Position: Q1 2026 in Review

Royal Bank of Canada reduced its Bright Minds Biosciences (DRUG) stake by 23% in Q1 2026, selling an estimated $9.74K and leaving 406 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #5715.

Royal Bank of Canada first reported a position in DRUG in Q1 2022 and has held it in 17 quarters since. The position peaked at $40K in Q4 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Royal Bank of Canada held 406 shares of Bright Minds Biosciences worth $30K as of Q1 2026.
  • Royal Bank of Canada sold 121 Bright Minds Biosciences shares in Q1 2026, an estimated $9.74K.
  • Bright Minds Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5715 holding.
  • Royal Bank of Canada first reported a position in Bright Minds Biosciences in Q1 2022 and has held it in 17 quarters since.
  • Royal Bank of Canada's Bright Minds Biosciences position peaked at $40K in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.